Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

Tina Roy; Joseph B. An; Kimberly Doucette; Aimee M. Chappell; David H. Vesole

doi:10.1080/10428194.2021.2010065

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

Tina Roy
, Joseph B. An
, Kimberly Doucette
, Aimee M. Chappell
, David H. Vesole

School of Medicine

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	759-761
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	63
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2021.2010065
State	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.2010065

Cite this

@article{30df5610c1734ff99f6a7ca467bfbfc8,

title = "Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression",

author = "Tina Roy and An, \{Joseph B.\} and Kimberly Doucette and Chappell, \{Aimee M.\} and Vesole, \{David H.\}",

year = "2022",

doi = "10.1080/10428194.2021.2010065",

language = "English",

volume = "63",

pages = "759--761",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

AU - Roy, Tina

AU - An, Joseph B.

AU - Doucette, Kimberly

AU - Chappell, Aimee M.

AU - Vesole, David H.

PY - 2022

Y1 - 2022

UR - https://www.scopus.com/pages/publications/85123834472

U2 - 10.1080/10428194.2021.2010065

DO - 10.1080/10428194.2021.2010065

M3 - Letter

C2 - 35076333

SN - 1042-8194

VL - 63

SP - 759

EP - 761

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this